Docetaxel as neoadjuvant chemotherapy in patients with advanced cervical carcinoma

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 26, Issue 5, 2003, Pages 477-482

  Vallejo, Carlos T ^a   Machiavelli, Mario R ^a   Pérez, Juan E ^a   Romero, Alberto O ^a   Bologna, Fabrina ^a   Vicente, Hernán ^a   Lacava, Juan A ^a   Ortiz, Eduardo H ^a   Cubero, Alberto ^a   Focaccia, Guillermo ^a   Suttora, Guillermo ^a   Scenna, Mirna ^a   Boughen, José M ^a   Leone, Bernardo A ^a  

^a GOCS Neuquén ^*

Author keywords

Cervical cancer; Docetaxel; Neoadjuvant chemotherapy

Indexed keywords

CIMETIDINE; DEXAMETHASONE; DIPHENHYDRAMINE; DOCETAXEL; METHYLPREDNISOLONE; RANITIDINE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTHRALGIA; ARTICLE; ASTHENIA; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CONJUNCTIVITIS; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; EDEMA; FEMALE; HUMAN; HYPERSENSITIVITY REACTION; INFECTION; LEUKOPENIA; MYALGIA; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; RASH; STOMATITIS; SURVIVAL TIME; UTERINE CERVIX CARCINOMA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; SURVIVAL ANALYSIS; TAXOIDS; UTERINE CERVICAL NEOPLASMS;

EID: 10744232829     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.coc.0000037109.12434.52     Document Type: Article

References (47)

1. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 1993;54:594-606.
2. Thigpen JT, Vance R, Puneky L, et al. Chemotherapy as a palliative treatment in carcinoma of the uterine cervix. Semin Oncol 1995;22:16-24.
3. Disaia PJ, Creasman WT. Invasive cervical cancer. In: Disaia PJ, Creasman WT, eds. Clinical gynecologic oncology. St. Louis: Mosby, 1993:58-125.
4. Piver MS, Chung WS. Prognostic significance of cervical lesion size and pelvic node metastases in cervical carcinoma. Obstet Gynecol 1975;46: 507-10.
5. Alvarez RD, Soong SJ, Kinney WK, et al. Identification of prognostic factors and risk groups in patients found to have nodal metastasis at the time of radical hysterectomy for early-stage squamous carcinoma of the cervix. Gynecol Oncol 1989;36:130-5.
6. Delgado E, Bundy B, Zaino R, et al. Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 1990;38:352-7.
7. Pérez CA, Grigsby PW, Camel HM, et al. Irradiation alone or combined with surgery in stage IB, IIA, and IIB carcinoma of uterine cervix: update of a nonrandomized comparison. Int J Radiat Oncol Biol Phys 1995;31:703-16.
8. Durrance FY, Fletcher GH, Rutledge FN. Analysis of central recurrent disease in stages I and II squamous cell carcinomas of the cervix on intact uterus. AJR Radium Ther Nucl Med 1969;106:831-8.
9. Gallion HH, van Nagell JR Jr, Donaldson ES, et al. Combined radiation therapy and extra-fascial hysterectomy in the treatment of stage IB barrel-shaped cervical cancer. Cancer 1985;56:262-5.
10. Rutledge FN, Wharton JT, Fletcher GH. Clinical studies with adjunctive surgery and irradiation therapy in the treatment of carcinoma of the cervix. Cancer 1976;38:596-602.
11. Prestayko AW, D'Aoust JC, Issell BF, et al. Cisplatin (cis-diammine dichloroplatinum II). Cancer Treat Rev 1979;6:17-39.
12. Vogl SE, Moukhtar M, Calanog A, et al. Chemotherapy for advanced cervical cancer with bleomycin, vincristine, mitomycin C, and cis-diammine dichloroplatinum (II) (BOMP). Cancer Treat Rep 1980;64: 1005-7.
13. Whitney CW, Sause W, Bundy BN, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative paraaortic lymph nodes. A Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 1999;17:1339-48.
14. Keys HM, Bundy BN, Stehman FB, et al. Cisplatin radiation and adjuvant hysterectomy for bulky stage Ib cervical carcinoma. N Engl J Med 1999;340:1154-61.
15. Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 1999;340:1137-43.
16. Peters WA III, Liu PY, Barret R, et al. Cisplatin, 5-fluorouracil plus radiation therapy are superior to radiation therapy as adjunctive therapy in high-risk, early-stage carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy [Abstract]. Proc Soc Gynecol Oncol 1999;28.
17. Rose PG, Bundy BN, Watkins J, et al. Concurrent cisplatin-based chemotherapy and radiotherapy for locally advanced cervical cancer. N Engl J Med 1999;340:1144-53.
18. Eifel PJ. Concurrent chemotherapy and radiation: a major advance for women with cervical cancer [Editorial]. J Clin Oncol 1999;17:1334-5.
19. Denis JN, Greene AE, Guenard D, et al. A highly efficient practical approach to natural Taxol. J Am Chem Soc 1988;110:5917-9.
20. Mangatal L, Adeline MT, Guenard D, et al. Application of the vicinal oxyamination reaction with asymmetric induction to the hemisynthesis of Taxol and analogues. Tetrahedron 1989;45:4177-90.
21. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by Taxol. Nature 1979;277:665-7.
22. Gueritte-Voegelein F, Guenard D, Lavelle F, et al. Relationships between the structure of Taxol analogues and their antimitotic activity. J Med Chem 1991;34:992-8.
23. Ringel I, Horwitz SB. Studies with RP 56976 (Taxotere): a semisynthetic analogue of Taxol. J Natl Cancer Inst 1991;83:288-91.
24. Harrison SD, Dykes DJ, Shepherd RV, et al. Responses of human tumor xenografts to Taxotere [Abstract]. Proc Am Assoc Cancer Res 1992;33: 526.
25. Choy H, Rodríguez F, Koester S, et al. Synergistic effects of Taxol Taxotere on radiation sensitivity on human tumor cell lines. Int J Radiat Oncol Biol Phys 1993;24:274-5.
26. Harrison SD, Dykes DJ, Shepherd RV, et al. Responses of human tumor xenografts to Taxotere [Abstract]. Proc Am Assoc Cancer Res 1992;33: 526.
27. Mauer A, Haraf D, Ferguson M, et al. Docetaxel-based combined modality therapy for locally advanced carcinoma of the esophagus and gastric cardia [Abstract]. Proc Annu Meet Am Soc Clin Oncol 1999;18: A963.
28. Fosella FV, Lee JS, Shin DM, et al. Phase II study of docetaxel for advanced or metastatic platinum refractory non-small cell lung cancer. J Clin Oncol 1995;1:645-51.
29. Dreyfus AI, Clark JR, Norris CM, et al. Docetaxel: an active drug for squamous cell carcinoma of the head and neck. J Clin Oncol 1996;14: 1672-8.
30. Extra J, Rousseau F, Bruno R, et al. Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. Cancer Res 1993;53:1037-42.
31. Bisset D, Setanoians A, Cassidy J, et al. Phase I and pharmacokinetic study of Taxotere (RP 56976) administered as a 24-hour infusion. Cancer Res 1993;53:523-7.
32. Pazdur R, Newman BM, et al. Phase I trial of taxotere: five-day schedule. J Natl Cancer Inst 1992;84:1781-8.
33. Burris H, Irvin R, Kuhn J, et al. Phase I clinical trial of taxotere given as either a 2-hour or a 6-hour intravenous infusion. J Clin Oncol 1993;11:950-8.
34. DeValeriola D, Brassinne C, Piccart M, et al. Phase I pharmacokinetic study of Taxotere (RP 56976) administered as a weekly infusion [Abstract]. Proc Am Assoc Cancer Res 1992;33:261.
35. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981;47:207-14.
36. Piver MS, Rutledge F, Smith JP. Five classes of extended hysterectomy for women with cervical cancer. Obstet Gynecol 1974;44:265-72.
37. Perry MC. Appendix-WHO toxicity guidelines. In: Perry MC, ed. The chemotherapy source book. Baltimore: Williams & Wilkins, 1992: 1132-44.
38. Kaplan EC, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:437-81.
39. Simes RJ, Zelen M. Exploratory data analysis and the use of the hazard function for interpreting survival data: an investigator's primer. J Clin Oncol 1985;3:1418-31.
40. Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984;2:1281-8.
41. Vallejo CT, Pérez JE, Dominguez ME, et al. Neoadjuvant chemotherapy with ifosfamide, cisplatin and vinorelbine in advanced squamous cell carcinoma of the cervix. Am J Clin Oncol 2000;23:481-6.
42. Noda K, Terajima Y, Ogita Y, et al. Phase II clinical study of RP56976 (docetaxel) in patients with carcinoma ovarii or carcinoma colli uteri. Gan To Kagaku Ryoko 1994;21:2471-7.
43. 2 intravenously over 1 hr every 21 days: a preliminary report [Abstract]. Proc Annu Meet Am Soc Clin Oncol 1996;15:A800.
44. Colevas AD, Norris CM, Tishler RB, et al. Phase I/II trial of outpatient docetaxel, cisplatin, 5-fluororacil, leucovorin (opTPFL) as induction for squamous cell carcinoma of the head and neck (SCCHN). Am J Clin Oncol 2002;25:153-9.
45. Bafaloukos D, Gogas H, Briassoulis E, et al. Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group. J Clin Oncol 2002;20:420-5.
46. Jones WB. New approaches to high-risk cervical cancer. Advanced cervical cancer. Cancer 1993;71:1451-9.
47. Lacava JA, Leone BA, Machiavelli M, et al. Vinorelbine as neoadjuvant chemotherapy in advanced cervical carcinoma. J Clin Oncol 1997;15: 604-9.